This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
A multicentre, double-blind, randomized controlled trial, carried out in 56 participating centres. The duration of followup was 6 months. All but 21 of the 2,099 patients had their follow-up survival status determined (99% of complete follow-up). Randomisation was conducted by a telephone call to a coordinating centre and was stratified by study site and whether the patient was having an acute myocardial infarction. All events were reviewed by an independent clinical endpoints committee, which remained blinded to treatment and required consensus of at least two reviewers for classification.
Analysis of effectiveness
It was reported that most comparisons were made based on intention to treat. The primary endpoint was the 30-day composite incidence of death from any cause, MI, coronary artery bypass surgery, repeat percutaneous coronary angioplasty (PTCA), or need for an endoluminal stent or insertion of an intra-aortic balloon pump to treat ischaemia. The primary endpoint for 6 month outcome was the composite of death, nonfatal MI, or the need for a repeat revascularisation (PTCA, coronary artery bypass surgery, or both). The risk of bleeding was also considered. There were no significant differences by treatment assignment in terms of the baseline features of the patients who had a successful initial procedure.
Effectiveness results
By 30 days, 12.8% of placebo bolus/placebo infusion patients had experienced a major ischaemic event (death, MI, urgent revascularisation), compared with 8.3% of c7E3 bolus/c7E3 infusion patients, yielding a 4.5% difference (35% reduction, p=0.008). At 6 months, the absolute difference in patients with a major ischaemic event or elective revascularisation was 8.1% between placebo bolus/placebo infusion and c7E3 bolus/c7E3 infusion patients (35.1% versus 27.0%; 23% reduction p=0.001). The c7E3 bolus/placebo infusion group had an intermediate outcome which was not significantly better than that of the placebo bolus infusion group. Patients receiving c7E3 bolus only, or c7E3 bolus/c7E3 infusion, had a significant increase in bleeding complications in the first 48 hours, with an approximate doubling of packed red-blood-cell transfusion rate (placebo bolus/placebo infusion 7%, c7E3 bolus/placebo infusion 14%, c7E3 bolus/c7E3 infusion 17%, p<0.001).
Clinical conclusions
These results extend the benefit of c7E3 bolus/c7E3 infusion from reducing abrupt closure and acute-phase adverse outcome to a diminished need for subsequent coronary revascularisation procedures.
Measure of benefits used in the economic analysis
The benefit measures were patients without ischaemic events and patients without ischaemic events and major bleeding.
Direct costs
Discounting of costs was not carried out due to the short time frame of the study. Quantities of resource use were not reported separately from the costs. The costs measured were those associated with inpatient care, laboratory tests, therapeutic and diagnostic procedures both within the cardiology department and other areas of the hospital, for events occurring during a 6-month post-treatment period. The boundary adopted was the hospital. A group of 119 patients who had previously participated in the HELVETICA trial or in the CAPTURE study (both studies having selection criteria and complications similar to the EPIC study) was used to estimate the marginal costs per event. Costs were computed by linking the various events to estimates of costs. Unit costs were mainly based on the internal cost information of a university hospital in the Netherlands. The Dutch tariffs were used for some diagnostic and therapeutic procedures. The price year was not clearly reported.
